357 results about "Cannabidiol" patented technology

The invention provides a hemostatic composition, a preparation method thereof and a hemostatic product. The hemostatic composition is prepared from the following raw material components in parts by mass: 0.01 to 0.5 part of cannabidiol, 10 to 150 parts of tannic acid modified carboxymethyl chitosan and 5 to 250 parts of crosslinked starch. The tannic acid modified carboxymethyl chitosan is prepared from the following raw material components in parts by mass: 45 to 55 parts of carboxymethyl chitosan and 0.5 to 1.5 parts of tannic acid. The cross-linked starch is prepared from the following raw materials in parts by mass: 95 to 105 parts of carboxymethyl enzymolysis starch and 2 to 5 parts of sodium trimetaphosphate. The hemostatic composition has a good hemostatic effect, and when the hemostatic composition is used in hemostatic products, the hemostatic products can have a good hemostatic effect.

The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

The present technology relates to a method of treating one or more symptoms of Full Methylation (Fmet) Fragile X Syndrome in a subject that includes administering an effective amount of cannabidiol to the subject such that one or more symptoms of Fragile X Syndrome are treated.

The invention relates to the use of cannabidiol (CBD), at a dose of greater than 300 mg / day, in combination with a standard anti-epileptic drug (SAED) which acts via sodium or calcium channels, for use in the treatment of epilepsy. The SAED is preferably one which •modities low-threshold or transient neuronal calcium currents, or •reduces high-frequency neuronal firing and sodium-dependent action potentials and enhances GABA effects. Preferred SAEDs are ethosuximide and valproate.

The present disclosure relates to the use of cannabidiol (CBD) for the treatment of Tuberous Sclerosis Complex (TSC). In particular the TSC is treatment resistant and is characterised by generalised seizures or focal seizures with impairment. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

The present technology relates to a method of treating one or more behavioral symptoms of Autism Spectrum Disorder (ASD) in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of ASD are treated in the subject.

The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.

The present invention relates to a group of cannabinoid derivatives as pharmaceutically active compounds and methods of preparation thereof. The cannabinoid derivatives of the invention are analogues of cannabidiol (CBD). CBD is a non-psychoactive cannabinoid which has been used to treat various diseases and disorders. While such treatments hold promise, there remains a need in the art for more effective treatments and this has been brought about by way of the cannabinoid derivatives of the invention

This disclosure herein describes the use of cannabidiol (CBD) with tetramethylpyrazine (TMP) to improve the bioavailability and efficacy of CBD. Behavioral studies indicate that the oral administration of CBD with TMP has a strong anxiolytic effect, increases social behavior in stressed rats, and alleviates anhedonia-like symptoms in stressed rats. These effects were significantly greater than observed with CBD alone, most likely due to increased CBD exposure with TMP administration and / or a metabolism effect of the co-administration of CBD and TMP.

The present invention pertains to a liposome comprising cannabidiol (CBD), a phospholipid component and optionally a sterol component, wherein the liposome comprises more than one bilayer, to related mixtures of liposomes, processes for manufacturing,medicalusesandcompositions.

The present invention relates to a cannabidiol (CBD) type cannabinoid compound for use as a medicament. The CBD-type cannabinoid, cannabidiol-C6 (CBD-C6), is a naturally occurring cannabinoid that can be found in minor quantities in the cannabis plant. Furthermore, the cannabinoid can be produced by synthetic means and a method for the production of CBD-C6 is described herein. In addition, disclosed herein are data which demonstrate the efficacy of CBD-C6 in models of disease.

The present disclosure relates to the use of cannabidiol (CBD) in the treatment of absence seizures. In particular, the disclosure relates to the use of CBD for reducing absence seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; CDKL5; Dup15q;, Jeavons syndrome; Myoclonic Absence Epilepsy; Neuronal ceroid lipofuscinoses (NCL) and brain abnormalities. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

The invention provides an industrial production method of cannabidiol, which comprises the following steps: 1) dissolving a cannabis sativa extract with a non-polar solvent, and carrying out first extraction with an alcoholic solution with a first concentration to obtain an oil phase 1 and a water phase 1, the cannabidiol content in the cannabis sativa extract being 40-60%; 2) performing secondary extraction on the oil phase 1 by using an alcoholic solution with a second concentration to obtain an oil phase 2 and a water phase 2; 3) carrying out third extraction on the oil phase 2 by using an alcoholic solution with a third concentration to obtain an oil phase 3 and a water phase 3; and 4) combining the water phase 2 and the water phase 3, concentrating, and crystallizing the concentrate, wherein the first concentration is more than the third concentration and the second concentration is less than the third concentration. According to the method provided by the invention, the production equipment is simple, the column chromatography separation is avoided, the production efficiency is greatly improved, and the ideal yield is obtained.

Pharmaceutical composition comprising one or more cannabinoids (e.g., cannabidiol; 15-25 % w / w), one or more cyclodextrins or cyclodextrin derivatives (e.g., α-cyclodextrin (alpha-CD) or hydropropyl-β

The present invention relates to the use of cannabidiol (CBD) in the treatment of patients with childhood-onset epilepsy syndromes who are concurrently taking the antiepileptic drug clobazam. When CBD is used in combination with clobazam caution should be taken. The patient may need to be cautioned and / or monitored for side effects of a drug-drug interaction 5 between the two medications. In particular the patient should be cautioned and / or monitored for the occurrence of pneumonia. In such a situation the dose of either the CBD and / or the clobazam may be required to be reduced.

The present invention relates to a cannabidiol (CBD) type cannabinoid compound for use as a medicament. The CBD-type cannabinoid, 6-hydroxy cannabidiol (6-0 H CBD), is a metabolite of CBD. The cannabinoid can be produced by synthetic means and a method for the production of 6-0 H CBD is described herein. In addition, disclosed herein are data which demonstrate the efficacy of 6-0 H CBD in a model of disease.

The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

The present invention relates to a cannabidiol (CBD) type cannabinoid compound for use as a medicament. The CBD-type cannabinoid, cannabidiol-C6 (CBD-C6), is a naturally occurring cannabinoid that can be found in minor quantities in the cannabis plant. Furthermore, the cannabinoid can be produced by synthetic means and a method for the production of CBD-C6 is described herein. In addition, disclosed herein are data which demonstrate the efficacy of CBD-C6 in models of disease.

The present technology relates to a method of treating one or more behavioral symptoms of autism spectrum disorder (ASD) in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of ASD are treated in the subject.

An injectable cannabidiol formulation for non-IV parenteral administration comprising, consisting essentially of, or consisting of: (a) a solvent system consisting of (i) an effective amount of at least one triglyceride oil; and (ii) an effective amount of at least one C1-C3 alkyl ester of a C6-C22 fatty acid; and (b) an effective amount of cannabidiol; wherein the formulation is free of water and ethanol, has a viscosity less than about 35 cP, and is phase stable and chemically stable. The formulation can further comprise at least one additional pharmaceutically acceptable excipient. Kits containing the formulation are also described.

The invention discloses a preparation method of a cannabidiol compound, the method synthesizes the cannabidiol compound from a resorcinol derivative and menthyl-2, 8-diene-1-ol under the catalysis of a condensing agent, and the method has the advantages of simple operation, high alkylation reaction site selectivity and the like, and is suitable for being developed into a large-scale production process.

A chemical composition for an oral pharmaceutical product is described having a therapeutically effective amount of one or more active pharmaceutical ingredients (API) including ibuprofen in combination with a cannabidiol (CBD) isolate.

The invention discloses a preparation method and application of a high-purity cannabidiol heptyl derivative CBDP, and belongs to the technical field of organic synthesis compounds. In order to solve the technical problems of low purity, complex process and high cost of cannabidiol heptyl derivatives in the prior art, the invention provides a preparation method with high purity and simple preparation process. The key points of the technical scheme are as follows: (1) 5-heptylresorcinol and (1S, 4R)-1-methyl-4-(1-methylvinyl)-2-cyclohexene-1-alcohol are dissolved in a solvent and react under the action of a Lewis acid catalyst, and a cannabidiol heptyl derivative CBDP is obtained; (2) dissolving a cannabidiol heptyl derivative CBDP in a solvent, reacting with a derivatization reagent, and purifying to obtain an intermediate 7; and (3) dissolving the intermediate 7 in a solvent, and purifying through an enzyme hydrolysis reaction to obtain the high-purity cannabidiol heptyl derivative CBDP.

A transdermal delivery composition for the delivery to skin and the penetration of the skin includes: (a) a therapeutic effective amount of a cannabinoid mixture, wherein the cannabinoid mixture comprises cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) at a weight ratio of about 1:20 to about 20:1; (b) a hydrophilic polymer / hydrophobic polymer adduct in an amount sufficient to hold the cannabinoid composition and provide a sustain release of the cannabinoid mixture after application to skin tissue over a time period of at least 6 hours; (c) a penetrant component in an amount sufficient to assist with a transdermal penetration of the cannabinoid mixture through skin tissue once the composition has been applied to skin tissue; (d) a surfactant component in an amount sufficient to stabilize the polymer adduct and release the cannabinoid mixture from the transdermal delivery composition upon application to skin tissue; and (e) at least about 70 wt. % water. A method of application of a transdermal delivery composition to skin tissue includes applying the transdermal delivery composition to skin tissue and spreading the composition to form a film on the skin tissue. A method for formulating a transdermal delivery composition based on a desired penetration weight ratio of CBD to THC through skin tissue includes selecting a formulation weight ratio of CBD to THC for formulating the composition, wherein the weight ratio is determined by multiplying the desired penetration weight ratio of CBD to THC by a CBD / THC delivery factor, wherein the CBD / THC delivery factor.

The invention relates to a preparation method and application of cannabidiol epoxide, and the method comprises the following steps: obtaining cannabidiol, adding the cannabidiol into a buffer solution containing a surfactant, and treating under a preset treatment condition to obtain a crude product; and separating and purifying the crude product through silica gel column gradient chromatography to obtain a cannabidiol epoxide finished product. Compared with a traditional oxidation method adopting a peroxide agent, the process for preparing the cannabidiol epoxide can be obtained in one step through air natural oxidation, the cannabidiol epoxide is greener, more environmentally friendly and safer, and the production cost is lower while it is guaranteed that operation is easy. Meanwhile, the cannabidiol CBD which is relatively mature in extraction process is adopted as a raw material, and compared with other cannabinoids which are extremely low in natural content, the cannabidiol CBD is easier to obtain.

The invention provides a wound dressing for wound hemorrhage. The wound dressing is prepared from the following components in parts by mass: 20 to 25 parts of cationic cassava starch, 10 to 13 parts of polyethylene glycol, 1.2 to 1.8 parts of xanthan gum, 0.1 to 0.2 part of cannabidiol, 6 to 8 parts of tannic acid modified chitosan, 1.8 to 2.5 parts of a polydopamine solution with the concentration of 5mg / mL and 1 to 1.5 parts of nano-hydroxyapatite. The wound dressing has an instant hemostatic effect and a long-acting tissue regeneration induction capability.

The invention relates to a method for specifically detecting tetrahydrocannabinol and hydride thereof by utilizing bridged beta-cyclodextrin, and belongs to the technical field of analysis and detection of supramolecular materials. The method comprises the following steps: firstly, combining 1, 6-hexamethylenediamine bridged bis-beta-cyclodextrin with an indicator to form a supramolecular probe; in a buffer system with a pH value of 9-11, tetrahydrocannabinol or a hydride thereof specifically competes to be combined with a cavity and displaces an indicator by utilizing a synergistic inclusion effect of a bridging subject and dissociation difference of guest molecules, so that the system is subjected to fluorescence quenching or color change, and a structural analogue cannabidiol does not generate obvious interference. The method solves the problems that the sensitivity is low and cannabidiol cannot be effectively distinguished in the prior art through cooperation of specific main body construction and environment regulation, has the advantages of being rapid in detection, high in specificity, high in accuracy and the like, and is suitable for environment monitoring and field screening.